

AMENDMENTS

IN THE CLAIMS

Please amend claims 1, 13-16, 27, 28, 31-33, 36, 48, and 49 as shown below. Please cancel claims 27-33 and 36 herein without prejudice to their renewal.

1. (Presently Amended) A method for treating ~~subject having~~ a hemoglobinopathy in a subject, the method comprising administering to the subject in need thereof a compound, ~~wherein the compound that~~ inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase, ~~and wherein the compound increases expression of the gene encoding γ -globin in a bone marrow-derived cell, a hematopoietic stem cell, or a blast-forming unit erythroid cell or population of bone marrow-derived cells,~~ thereby treating the hemoglobinopathy in the subject.
- 2-11. (Previously Canceled)
12. (Previously Amended) The method of claim 1, wherein the hemoglobinopathy comprises an alteration in the level, structural integrity, or activity of adult β -globin.
13. (Presently Amended) The method of claim 1, wherein the hemoglobinopathy is selected from the group consisting of β -thalassemias and sickle cell syndromes.
14. (Presently Amended) The method of claim 13, wherein the β -thalassemia is selected from the group consisting of β^0 -thalassemia and β^+ -thalassemia.
15. (Presently Amended) The method of claim 13, wherein the sickle cell syndrome is selected from the group consisting of sickle trait, sickle β -thalassemia, and sickle cell anemia.
16. (Presently Amended) The method of claim 1, wherein administering the compound increases the proportion of fetal hemoglobin relative to non-fetal hemoglobin produced by the bone marrow-

~~derived cell, the hematopoietic stem cell, or the blast-forming unit erythroid cell or population of cells in the subject is increased.~~

17-26. (Previously Canceled)

27-33. (Canceled Herein)

34-35. (Previously Canceled)

36. (Canceled Herein)

37-47. (Previously Canceled)

48. (Presently Amended) The method of claim 1, wherein the compound that inhibits HIF prolyl hydroxylase ~~inhibitor~~ is selected from the group consisting of an iron chelator, a structural mimetic of 2-oxoglutarate-mimetic, and a proline analog.

49. (Presently Amended) The method of claim 48, wherein the structural mimetic of 2-oxoglutarate-mimetic inhibits HIF prolyl hydroxylase competitively with respect to 2-oxoglutarate and noncompetitively with respect to iron.